Reiterated Buy on Atai Beckley as Robust EMP-01 Phase IIa Data and Solid Cash Position Support $16 Price Target

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Atai Beckley N.V.. The associated price target remains the same with $16.00.

Justin Walsh has given his Buy rating due to a combination of factors tied to the latest EMP-01 Phase IIa data in social anxiety disorder, where patients on the drug showed greater willingness to engage in daily social situations and work activities versus placebo. He notes that the trial’s rigorous double-blind, randomized, placebo-controlled design, absence of adjunctive psychotherapy, and achievement of its primary safety and tolerability endpoint all support the robustness of these results.

Walsh also emphasizes that EMP-01 was generally well-tolerated, with only mild to moderate adverse events, no serious safety signals, and no reports of suicidal ideation, alongside a statistically meaningful improvement on standard anxiety and clinician global impression scales relative to placebo. Combined with Atai Beckley’s solid cash position and an increasingly supportive regulatory backdrop for psychedelic-based therapies, he remains cautiously optimistic on the long-term clinical and commercial opportunity, justifying a reiterated Buy rating and a $16 price target.

In another report released today, Needham also reiterated a Buy rating on the stock with a $14.00 price target.